Clinical Research of Individualized Therapy in Advanced Non-Small Cell Lung Cancer Guiding by & Nbsp;detection of ERCC1 Protein

GAO Zhi-qiang,HAN Bao-hui,SHEN Ce,JIN Xian-qiao,DONG Jing-cheng,WAN Huan-ying,TANG Jie,SHEN Jie,GU Ai-qin,JIANG Li-yan

DOI: https://doi.org/10.3969/j.issn.1007-3969.2013.05.002

2013-01-01

Abstract:10.3969/j.issn.1007-3969.2013.05.002

What problem does this paper attempt to address?

Randomized and controlled clinical research of personalized therapy for advanced non-small cell lung cancer according to ERCC1 and RRM1

CHEN Jia,HE Song,ZHANG Xiao-dong,GUO Yan,ZHU Ya-fang,JI Zhi-gu,LU Jun-guo,TAO Yu,ZHU Xing-hua,WANG Jian-hong,YANG Shu-yun,TAN Qing-he

DOI: https://doi.org/10.3969/j.issn.1672-2353.2012.09.008

2012-01-01

Abstract:Objective To select sensitive drugs according to the detection results of excision repair cross-complementation group 1(ERCC1) and ribonucleotide reductase M1(RRM1) in advanced non-small cancer lung cancer(NSCLC) patients and observe the effect differences so as to guide individual treatment.Methods Combined detection of ERCC1 and RRM1 of tumor cells was performed in advanced NSCLC patients diagnosed pathologically.The patients were divided into two groups with a proportion of 2:1.The control group received gemcitabine and cisplatin,while the gene group was divided into four subgroups according to ERCC1 and RRM1 and received individual therapy separately.The short-term and long-term effects were observed.Results A total of 174 patients were observed,and the overall efficacy rate was 44.2%.The efficacy rate was 37.5% in the control group and 47.5% in the gene group.The difference was statistically insignificant.The efficacy rate of ERCC1(-)(56.7%) was higher than that of ERCC1(+)(37.9%)in gene group,and the difference was statistically significant.The median progression-free survival,median survival and 1 year survival rate in each group had no significant difference.Conclusion The use of individual therapy in patients with lower expressions of ERCC1 can obtain higher efficacy rate,while the patients with higher expressions of ERCC1 may have drug resistance to platinums.
Clinical study on personalized treatment for advanced NSCLC guided by ERCC 1 protein detection

Zhi-Qiang Gao,Ai-Qin Gu,Jie Shen,Hui-Min Wang,Li-Yan Jiang,Hua Zhong,Chun-Lei Shi,Jin-Su Huang,Yi-Zhuo Zhao,Li-Wen Xiong,Bo Jin,Tian-Qing Chu,Bao-Hui Han

2017-01-01

Abstract:Background & Objective: Excision repair cross complementing 1 (ERCC1) participates in the resistance of non-small cell lung cancer (NSCLC) to platinum-based chemotherapy drug. This study aimed to explore the role of ERCC1 protein expression in personalized treatment for advanced NSCLC patient and its significance. Method: From January 2010 to December 2011, 159 advanced stage (stage IIIB-IV) NSCLC patients were enrolled. The expression of ERCC1 protein in lung cancer tissue of the patient was detected by immunohistochemical method. In a ratio of 2:1, patients were randomly divided into either the personalized treatment group or the standard treatment group. The standard treatment group adopted the platinum-based chemotherapy regimen, namely, gemcitabine/cisplatin or navelbine/cisplatin. In personalized treatment group, patients with high ERCC1 protein expression received gemcitabine/navelbine, and those with low ERCC1 protein expression received gemcitabine/cisplatin or navelbine/ cisplatin. The main observed indices included response rate, overall survival and time to progression. Group comparison was conducted by chi-square test. Comparison of one-year survival rate and survival was conducted by Life table and Kaplan-Meier method. Results: Follow-up data were up to December 31, 2014. The response rate of the standard treatment group and the personalized treatment group was 26.4% and 27.4%, respectively. The difference of the two groups was not statistically significant (P=0.899). The median survival was 9.4 months (95% CI was 7.88-10.92 months) in the standard treatment group and 13.2 months (95% CI was 12.34-14.06 months) in the personalized treatment group. The difference of two groups was statistically significant (P=0.045). The time to progression was 5.0 months (95% CI was 3.84-6.16 months) in the standard treatment group and 4.7 months (95% CI was 4.03-5.37 months) in the personalized treatment group, without significant difference (P=0.369). The one-year survival rate of the standard treatment group and the personalized treatment group was 41.5% and 46.2%, respectively, without significant difference (chi-square value=0.318, P=0.572). Conclusion: Compared with the standard treatment group, the median survival of the personalized treatment group is extended. However, the personalized treatment for advanced NSCLC guided by ERCC1 protein detection does not show advantages in response rate, survival and time to progression. Additional clinical studies are needed to optimize the detection of biomarkers so as to guide reasonable selection of clinical chemotherapy regimens.
ERCC1 Protein As a Guide for Individualized Therapy of Late-Stage Advanced Non-Small Cell Lung Cancer.

Zhiqiang Gao,Baohui Han,Jie Shen,Aiqin Gu,Dajiang Qi,Jinsu Huang,Chunlei Shi,Liwen Xiong,Yizhuo Zhao,Liyan Jiang,Huimin Wang,Yurong Chen

DOI: https://doi.org/10.3892/etm.2011.276

IF: 2.7

2011-01-01

Experimental and Therapeutic Medicine

Abstract:Excision repair cross-complementation group 1 (ERCC1) protein has been associated with cisplatin resistance. The objective of this study was to investigate the correlation between ERCC1 protein levels and the therapeutic effect of individualized therapy in advanced non-small cell lung cancer (NSCLC). A total of 190 advanced NSCLC patients were included in this study. Patients were randomized into either the individualized therapy group or the standard therapy group at a ratio of 2:1. Patients in the standard therapy group were treated with either gemcitabine plus cisplatin or vinorelbine plus cisplatin. The expression of ERCC1 protein in lung cancer tissues of patients from the individualized therapy group was detected with immunohistochemistry. Patients with low ERCC1 levels received either gemcitabine plus cisplatin or vinorelbine plus cisplatin, and patients with high levels received gemcitabine plus vinorelbine. The main outcome assessments were response rate (RR), overall survival (OS) and time to progression (TTP). Follow-up data were recorded until September 30, 2010. RR, 1-year survival rate and TTP were not statistically significant. The median survival time was 10.10 months in the standard therapy group (95% CI 8.48-11.92) and 13.59 months in the individualized therapy group (95% CI 11.86-14.74). The difference in median survival time was significantly different between these groups (P=0.036). The median survival time was longer in the individualized group compared to the standard therapy group. ERCC1 protein expression in advanced NSCLC patients, however, was not significantly correlated with RR, OS and TTP in the individualized therapy group. Therefore, this study suggests that ERCC1 protein levels should be assessed in combination with additional biomarkers to determine an optimal index for individualized therapy in advanced NSCLC patients.
Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Chenyi Ren,He Cao,Jing Zheng,Wenjia Sun,Jianya Zhou

DOI: https://doi.org/10.3779/j.issn.1009-3419.2023.102.14

2023-01-01

Abstract:Lung cancer is the most common malignancy in the world and the leading cause of cancer death. Human epidermal growth factor receptor 2 (HER2) positive non-small cell lung cancer (NSCLC) refers to the NSCLC caused by mutation, amplification or overexpression of the HER2 gene, resulting in its dysfunction. HER2 is the most active receptor in the HER family and can combine with other members to form dimers, which can activate multiple signaling pathways and regulate cell proliferation, differentiation, migration and apoptosis. In NSCLC, HER2 positivity is usually considered a poor prognostic marker. At present, the diagnosis and treatment of HER2-positive NSCLC are not mature. Immunohistochemistry (IHC), next generation sequencing (NGS) and other technologies are often used to detect the positive status of HER2 mutation, amplification or overexpression. In previous studies, antitumor drugs did not show ideal therapeutic effects in HER2-positive NSCLC. However, in recent years, related researches have shown that antibody-drug conjugates (ADCs) and new tyrosine kinase inhibitors (TKIs) in targeted therapy show good antitumor activity against HER2 positive NSCLC. This article summarized the progress in diagnosis and treatment of HER2-positive NSCLC, so as to provide reference for subsequent researches. .
Clinical Research of Individualized Therapy in Advanced Esophageal Cancer Based on the ERCC1 C8092A Genotype.

Yi-Wei Yao,Yi-Fu He,Xing-Hua Han,Chu-Shu Ji,Bing Hu

DOI: https://doi.org/10.3892/ol.2018.8894

2018-01-01

Oncology Letters

Abstract:The present study aimed to explore the role and clinical value of the detection of Excision repair cross-complementing 1(ERCC1) C8092A polymorphisms in individualized therapy of patients with advanced esophageal cancer. A total of 127 patients with advanced esophageal cancer were enrolled between January 2010 and January 2014 in Anhui Provincial Hospital. Patients were randomly assigned in a 1:2 ratio to a standard treatment group or an individualized treatment group, respectively, prior to ERCC1 C8092A assessment. Patients in the standard treatment group were treated with paclitaxel and cisplatin. The DNA was obtained from the peripheral blood of individualized treatment patients, amplified by PCR and sequenced to determine the ERCC1 C8092A polymorphism prior to the administration of chemotherapies. Patients with the ERCC1 C8092A genotype of A/A or A/C received paclitaxel and cisplatin, and those with the genotype of C/C received paclitaxel and fluorouracil. The primary endpoint was response rate (RR). The secondary endpoints included toxicity of chemotherapy, progression-free survival (PFS) and overall survival (OS) times. Differences between the groups were evaluated by χ2 test. Differences in survival were analyzed by Kaplan-Meier survival curves. The survival rate was analyzed by log-rank test. Follow-up data was obtained until December 2015. The RR was obtained for 15 patients (34.8%) in the standard treatment group and 45 patients (53.6%) in the individualized treatment group (χ2=3.095; P=0.046). For adverse events, nausea and vomiting and anemia were significantly decreased in the individualized treatment group compared with the standard treatment group (P=0.001 and P=0.004, respectively). The median progression free survival time was 4.4 months [95% confidence interval (CI)3.8-5.0 months] in the standard treatment group and 6.6 months (95% CI, 5.8-7.4 months) in the individualized treatment group (P=0.018). The median overall survival time was 11.4 months (95% CI, 10.1-12.7 months) in the standard treatment group and 14.2 months (95% CI, 13.2-15.2 months) in the individualized treatment group (P=0.008). The RR, toxicity of chemotherapy, PFS and OS were significantly improved in the individualized treatment group compared with the standard treatment group. Detection of ERCC1 gene polymorphisms maybe performed for patients with advanced esophageal cancer to improve individualized therapy, which requires additional study.
Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

TAN Fen-lai,WANG Yin-xiang,YUAN Xiao-fen,DING Lie-ming,HU Bei,ZHANG Li,ZHOU Jian-ying,SHENG-TU Jian-zhong,SUN Yan

2011-01-01

Abstract:Non-small cell lung cancer(NSCLC) is the leading cause of cancer mortality worldwide.The management of NSCLC has changed dramatically in the last decade.A number of well documented clinical studies demonstrated that the epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) showed a better survival benefit comparing to the standard treatments in patients with advanced/metastatic NSCLC.EGFR-TKIs,including gefitinib and erlotinib,have been used in first-line,second-line and more other settings with obvious survival benefits in a subgroup of patients with EGFR mutations.Moreover,icotinib,a novel EGFR-TKIs developed by BetaPharma Inc.,has finished its phase III trial(ICOGEN) with encouraging efficacy and safety profile in China recently.This review will summarize the results of clinical trials of erlotinib,gefitinib or icotinib for patients with advanced NSCLC.
Expression of ERCC1,RRM1 and BRCA1 in Tissues of Advanced Non-Small Cell Lung Cancer

GAO Zhi-qiang,HAN Bao-hui,SHEN Jie,GU Ai-qin,QI Da-jiang,HUANG Jin-su,SHi Chun-lei,XIONG Li-wen,ZHAO Yi-zhuo,JIANG Li-yan,WANG Hui-min,CHEN Yu-rong

DOI: https://doi.org/10.3969/j.issn.1674-8115.2011.03.009

2011-01-01

Abstract:Objective To investigate the expression of DNA repair gene family members of ERCC1,RRM1 and BRCA1 in tissues of advanced non-small cell lung cancer(NSCLC),and explore its clinical significance. Methods The expression of ERCC1,RRM1 and BRCA1 protein in 122 cases of advanced NSCLC was detected by immunohistochemical methods.The relationship between the expression of ERCC1,RRM1 and BRCA1 protein and the clinical characteristics,response to chemotherapy and prognosis were explored. Results The positive expression of ERCC1,RRM1 and BRCA1 protein in 122 cases was 47.5%,35.2% and 46.7%,respectively.There was no significant correlation between the positive expression of ERCC1 and RRM1 protein and gender,age,smoking status,ECOG physical status scale score,clinical stages and histological types(P0.05),and the expression of BRCA1 protein in females(63.6%) was significantly higher than that in males(40.4%).There was no significant difference in response rates to chemotherapy,median survival time and 1-year survival rate between patients with positive expression of ERCC1 and BRCA1 protein and those with negative expression of ERCC1 and BRCA1 protein(P0.05).Patients with positive expression of RRM1 protein had significantly lower response rates to chemotherapy and 1-year survival rate than those with negative expression of RRM1 protein(P0.05). Conclusion The expression of RRM1 protein in cancer tissues is closely related to the response to chemotherapy and prognosis in patients with advanced NSCLC.
Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

T. B. Wang,N. L. Zhang,S. H. Wang,H. Y. Li,S. W. Chen,Y. G. Zheng

DOI: https://doi.org/10.4238/2014.may.9.15

2014-01-01

Genetics and Molecular Research

Abstract:We examined mRNA expression levels of ERCC1, BRCA1, RRM1, and human beta-tubulin-III (TUBB3) in non-small-cell lung carcinoma (NSCLC) patients and investigated the association between expression of these genes and the clinical outcome of NSCLC treatment. A total of 366 patients who underwent surgery for NSCLC were included in this study. All patients received third-generation platinum-based chemotherapy as first-line treatment. The relative cDNA quantification for ERCC1, RRM1, BRCA1, and TUBB3 was determined using a fluorescence-based, real-time detection method. We found that low expression of ERCC1 and BRCA1 was associated with a good response to platinum-based chemotherapy, with an odds ratio [95% confidence interval (CI)] of 2.09 (1.33-3.27) and 2.92 (1.85-4.62), respectively. Multivariate Cox regression analysis indicated that patients with low expression of ERCC1 and BRCA1 attained a longer overall survival time than those with high expression, with a hazard ratio (95% CI) of 0.42 (0.23-0.77) and 0.39 (0.21-0.71), respectively. However, RMM1 and TUBB2 expressions were not correlated with clinical outcome of NSCLC. In conclusion, we found that low expression of ERCC1 and BRCA1 can be useful for selecting NSCLC patients who would benefit from chemotherapy and warrants further investigation in prospective studies.
Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in non-small cell lung cancer

Jing LUO,Mei-qing XU,Ming-fa GUO,Da-zhong WEI,Chang-qing LIU,Xiang-xiang SUN

DOI: https://doi.org/10.3969/j.issn.1007-3969.2014.02.009

2014-01-01

Abstract:Background and purpose:High expression of excision repair cross-complementing 1 (ERCC1) is related to resistance in patients treated with platinum-containing regimens. The ERCC1 antibody 8F1 was usually used in past studies, but it was found to have no-speciifcity recently. This study aimed to investigate the predictive role of a new ERCC1 antibody 4F9 to platinum chemotherapy in non-small cell lung cancer (NSCLC) patients. Methods:Expression of ERCC1 was detected using antibody 4F9 by immunohistochemistry (IHC) in 72 NSCLC tissues. The relationship between the expression of ERCCl and the clinical pathological parameters, the efficacy of platinum chemotherapy and overall survival of patients were explored by statistical analysis. Results: The high expression of ERCCl protein was 55.5%in 72 cases. There was no signiifcant correlation between the ERCC1 expression with gender, age, pathological type, clinical stage and lymphatic metastasis (P>0.05). Patients with low expression of ERCC1 had signiifcantly higher response rates to platinum chemotherapy, longer median survival time and 2-years survival rate comparing with those with high expression of ERCC1 (62.5%vs 37.5%;22.9 vs 18.4 month;46.9%vs 37.5%), respectively (P<0.05). Conclusion:The expression analysis of ERCC1 using new ERCC1 antibody 4F9 by IHC method is helpful to assign chemotherapeutic regimen, and guide individual platinum chemotherapy for post-operation patients.
A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Feng Jiang,Heng Zhao,Xiaofei Li,Lunxu Liu,Yang Liu,Jian Hu,Xiangning Fu,Yin Li,Yijun Xu,Deruo Liu,Haiying Yang,Lin Xu

DOI: https://doi.org/10.1200/JCO.2018.36.15_suppl.e20523

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e20523 Background: Clinical characteristics of lymph metastases are hetergeneous in the patients with T1 non-small cell lung cancer (NSCLC). Preoperative assessment of lymph metastases is essential to determine the appropriate treatment regimens. The study was designed to evaluate those potential factors that may influence lymph metastases. Methods: We conduct the study based on a national collaborative prospective lung cancer database (designed by LinkDoc Technology Co, Ltd.). The patients with pathologically diagnosed T1 non-small cell lung cancer who received surgical resection from 2014 to 2017 were enrolled. The univariate and multivariate logistic regression analyses were performed to analyze the risk factors that influnce lymph metastases. Results: A total of 10885 subjects were recruited in the study including 1808 patients with lymph metastases (16.6%) (N1: 640 patients/5.9%; N2: 1159 patients/10.6%). Of all the pN2 patients, 754(65.1%) patients were observed with N1 lymph nodes and 405 (34.9%) patients with skip metastases. The univariate and multivariate analyses showed the CEA levels before surgeries, tumor size, degree of differentiation, and tubular cancer embolus were potential risk factors of lymph metastases in the total population and in N2 population. The tuerculosis comorbidity was also found to be significantly related to lymph metastases. In the pN2 population, age and smoking history were predictive for N2 skip metastases. Conclusions: The relevance between clinical and tumor biological characteristics of the NSCLC patients, and lymph metastases were demonstrated in the Chinese real-world study that will offer clinical complementary guidance on management of T1 NSCLC patients in practice. Clinical trial information: NCT03413956.
Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Jingyao Li,Yang Qiu,Junxiu Yi,Xi Liu,Shixin Zhang,Deli Tan,Tao Jing,Yi Liao,Meng Tang,Jie Liu,Haidong Wang

DOI: https://doi.org/10.1155/2021/8820691

IF: 4.501

2021-09-23

Journal of Oncology

Abstract:Objective. To investigate the clinical significance of the mRNA expression of RRM1, TUBB3, and ERCC1 in non-small-cell lung cancer (NSCLC) tissues for the selection of adjuvant/postoperative chemotherapy regimens. Methods. Patients diagnosed with stage Ib-IIIa NSCLC were enrolled and randomly divided into a control group (undetected group) and an experimental group (detected group) after radical operation. The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The mRNA expression of RRM1, TUBB3, and ERCC1 was detected in the experimental group before chemotherapy, and based on the detected expression, the chemotherapy regimen of cisplatin plus gemcitabine or cisplatin plus paclitaxel was chosen. The disease-free survival (DFS) of the control group and experimental group was compared. Results. Pathological type, stage, gene expression detection, and treatment method were not significantly correlated with DFS ( P > 0.05 ). In the subgroups treated with gemcitabine, the median DFS was 17 months in the detected group and 10.5 months in the undetected group (hazard ratio = 0.2147, 95% confidence interval: 0.07909–0.5827, P = 0.0025 ). Multivariate regression analysis was performed to analyse whether gene expression detection was independently correlated with DFS in the subgroups treated with gemcitabine ( P = 0.025 ). In the detected group, the prognosis of patients with low expression of RRM1 was better than that of patients with high expression of RRM1 after paclitaxel treatment ( P = 0.0039 ). Conclusions. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.

oncology
First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Ying Li,Lin Run Wang,Jian Chen,Yan Lou,Guo Bing Zhang

DOI: https://doi.org/10.1155/2014/960458

2014-01-01

Disease Markers

Abstract:AIM:To evaluate the predictive value of RRM1, ERCCl, and BRCA1 expression in Chinese NSCLC patients treated with gemcitabine and cisplatin.METHODS:Real-time fluorescent quantitative PCR was used to determine the RRM1, ERCC1, and BRCA1 mRNA expression levels of peripheral blood in late-stage NSCLC patients. The relationship between peripheral blood and mRNA expression in tumor tissues was analyzed further.RESULTS:In terms of the tumor susceptibility to chemotherapy, the response rate in the low-RRM1-expression group was significantly greater than in the high-expression group (52.9% versus 5.9%, χ(2) test, P = 0.007). Subjects with low peripheral blood RRM1 expression survived longer than those with high RRM1 expression (15.5 versus 12.0 months, logrank 3.980, P = 0.046). Linear correlations were observed between peripheral blood and tumor tissue expression levels for RRM1 (R (2) = 0.045, P = 0.048) and BRCA1 (R(2) = 0.021, P = 0.001).CONCLUSION:Our study demonstrates increased survival and superior efficacy of gemcitabine and cisplatin combination chemotherapy in the treatment of NSCLC patients with low peripheral blood RRM1 expression. The linear correlations of the relative expression of mRNA were observed between peripheral blood and tumor tissue expression levels for RRM1 and BRCA1. RRM1 gene expression may contribute to chemotherapy sensitivity and may be an indicator of survival. It was significant to individual chemotherapy of patients with advanced NSCLC who do not have sufficient tumor tissue.
Analysis of A Case of Advanced Non-small Cell Lung Cancer Treated with Individualized Therapy

WANG Liuchun,LIU Zhujun,XIAO Jianyu,YUAN Jing,LI Kai

DOI: https://doi.org/10.3969/j.issn.1000-8179.2009.15.015

2009-01-01

Chinese Journal of Clinical Oncology

Abstract:The prognosis of patients with non-small cell lung cancer is poor and the overall survival is 5-6 months and the one-year survival rate is 20%～25%. Regular chemotherapy can prolong patient survival for 2～3 months. Currently, new treatments such as antiangiogenic and target therapy have appeared. At the same time individualized therapy according to the performance of patients, pathological type and biological characteristics of tumor cell is considered in order to reach good therapeutic effect and survival. We will introduce one patient with non-small cell lung cancer treated with individualized therapy in our department. Chemotherapy and anti-vascular therapy achieved good results in this patient. CT perfusion and cECs were applied to evaluate the effect of the therapy.
Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer

Rafael Rosell,Christian Manegold,Teresa Moran,Pilar Garrido,Remei Blanco,Pilar Lianes,Rolf Stahel,Jose Manuel Trigo,Jia Wei,Miquel Taron

DOI: https://doi.org/10.3816/clc.2008.s.012

IF: 4.84

2008-01-01

Clinical Lung Cancer

Abstract:Metastatic non-small-cell lung cancer remains a fatal disease with a median survival of < 1 year. A critical challenge is to develop predictive markers for customizing platinum-based treatment. The first studies focused on the excision repair cross-complementing 1 (ERCC1) gene in this difficult task. Several layers of evidence indicate that ERCC1 mRNA expression could be a predictive marker for cisplatin alone or in combination with certain drugs such as etoposide, gemcitabine, and 5-fluorouracil but not in combination with antimicrotubule drugs. Several retrospective studies demonstrated an impressive survival advantage for gemcitabine plus cisplatin but not for other combinations in tumors with low ERCC1 expression. A customized phase III ERCC1-based trial met the primary endpoint of improvement in response but not in survival, leading us to hypothesize that docetaxel might not be the most appropriate partner for cisplatin in the presence of low ERCC1 levels or for gemcitabine in the presence of high ERCC1 levels. A phase II study demonstrated the feasibility of combining carboplatin, gemcitabine, docetaxel, and vinorelbine according to ERCC1 and ribonucleotide reductase subunit M1 expression levels. These findings highlight the importance of continual learning, and decision-making strategies for customizing treatment should reflect the limitations of our knowledge.
Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.

Fang-Fang Shen,Wei Guo,Rui-Fen Tian,Yi Guo,Yan-Li Yang,Xia Song

DOI: https://doi.org/10.21037/tlcr.2020.01.21

2020-01-01

Translational Lung Cancer Research

Abstract:Non-small cell lung cancer (NSCLC) is a profoundly devastating disease that is the leading cause of cancer-related death worldwide. With the rapid development of next-generation sequencing (NGS), which has supplied the ability to decode tumors at the DNA level, so that targeted therapy plays a crucial role in improving NSCLC survival. We first reported a 32-year-old Chinese female patient received the ninth-line treatment, who was initially diagnosed with advanced NSCLC with EGFR 19 deletion. The patient had a satisfactory clinical response to initial gefitinib treatment. Subsequently, an EGFR T790M mutation was detected from plasma-derived circulating tumor DNA (ctDNA) by ddPCR after disease progression, while NGS did not. Osimertinib was still tried but had no therapeutic effect. Then the disease even progressed on the administration of chemotherapy and gefitinib in succession. Rebiopsy for NGS detection was performed, and gefitinib plus anlotinib/vemurafenib were tried. And then, gefitinib plus crizotinib were administrated for MET amplification after the third biopsy. Furthermore, chemotherapy combined with immunotherapy was performed due to the PD-L1 positive expression. Up to now, osimertinib treatment was undertaken to base on an EGFR exon 20 T790M mutation using NGS-based genotyping in cerebrospinal fluid (CSF) ctDNA. Tumor genome dynamic monitoring can identify tumor driving genes and drug resistance mechanisms to guide tumor treatment. This study found that the total survival time of advanced NSCLC patients was more than four years after chemoradiotherapy and targeted therapy, indicating the significance of dynamic monitoring of gene alterations for cancer treatment.
New Approaches for Individual Treatment of Advanced Non-Small Cell Lung Cancer

Shun Lü

2011-01-01

Abstract:Lung cancer continues to be the leading cause of cancer death worldwide,and non-small cell lung cancer is the most common type of lung cancer.Despite many clinical trials of platinum-based chemotherapy in combination with various drugs,the median survival time of patients with non-small cell lung cancer remains poor.The overall 5-year survival rate of patients with advanced non-small cell lung cancer is approximately 15%,and has improved only marginally in recent years.A recent milestone in this field has been the development of molecular-targeting drugs,among which gefitinib and erlotinib targeting the epidermal growth factor receptor(EGFR) have improved the efficacy of therapy for non-small cell lung cancer.Anti-angiogenetic drug,such as bevacizumab,has been used in the treatment of non-small cell lung cancer.Moreover,the discovery of echinoderm microtubule-associated protein-like 4/anaplastic lymphoma kinase(EML4-ALK) fusion gene has contributed to the marvelous progress in research of lung cancer.In this review,the drugs used in individualized treatment of advanced non-small cell lung cancer,such as EGFR-tyrosine kinase inhibitors and EML4-ALK fusion gene inhibitors are introduced.
Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Xiao-ping Qian,Bao-rui Liu,Mei-qi Shi,Xin-zi Liu,Wen-jing Hu,Zheng-yun Zou,Jia Wei

DOI: https://doi.org/10.3760/cma.j.issn.0253-3766.2009.01.008

2009-01-01

Abstract:OBJECTIVE:To investigate the correlation of the mRNA expression level of excision repair cross-complementing group 1 (ERCC1) gene with clinicopathological parameters and clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy.METHODS:The mRNA expression of ERCC1 in formalin-fixed paraffin-embedded primary tumor specimens was measured by real-time quantitative reverse transcriptase polymerase chain reaction. The association between ERCC1 expression levels and clinicopathological parameters in NSCLC patients was analyzed.RESULTS:The median value of ERCC1 mRNA expression level compared with beta-actin in tumor specimens of 61 NSCLC patients was 0.48. There was no correlation between ERCC1 expression and clinicopathological parameters. Patients with low expression of ERCC1 mRNA (less than 0.35, 0.28, respectively) had a significantly longer median time to progression (TTP) (14.3 vs. 8.0 months, P = 0.028) and overall survival (OS) (28.4 vs. 12.9 months, P = 0.0064) than those with high expression. Multivariate analysis showed that a low ERCC1 mRNA expression was an independent factor for OS.CONCLUSION:Our findings suggest that intratumoral ERCC1 mRNA expression level, although is uncorrelated with clinicopathological parameters, is an independent predictive marker for survival of the patients with NSCLC receiving platinum-based chemotherapy, and may provide critical information for personalized chemotherapy.
Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Xinghao Ai,Jiuwei Cui,Jiexia Zhang,Rongrong Chen,Wen Lin,Congying Xie,Anwen Liu,Junping Zhang,Weihua Yang,Xiaohua Hu,Xiaohua Hu,Qiong Zhao,Chuangzhou Rao,Yuan-Sheng Zang,Ruiling Ning,Pansong Li,Lianpeng Chang,Xin Yi,Shun Lu

DOI: https://doi.org/10.1158/1078-0432.ccr-20-3063

IF: 13.801

2020-11-13

Clinical Cancer Research

Abstract:PURPOSE: Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers is not always applicable. This prospective clinical trial was to investigate whether paired tissue and circulating tumor DNA (ctDNA) could describe the clonal architecture of advanced non-small cell lung cancer (NSCLC) and its association with clinical outcome (NCT03059641).PATIENTS AND METHODS: Paired tumor and plasma ctDNA samples were sequenced by target-capture deep sequencing of 1,021 genes. Clonal dominance analysis was performed on the basis of PyClone.RESULTS: Overall, 300 treatment-naïve patients with stage IIIB-IV NSCLC were recruited from 14 centers. Of the 94 patients with available ctDNA data for EGFR clonal architecture analysis, 72 (76.6%) showed EGFR as the dominant clone. The median progression-free survival was longer for these patients than for the 22 patients whose EGFR was nondominant clone [11 vs. 10 months; HR, 0.46; 95% confidence interval (CI), 0.24-0.88; P = 0.02]. The difference was more significant if both tissue and ctDNA defined EGFR as dominant clone (n = 43) versus those not (n = 8; 11 vs. 6 months; HR, 0.13; 95% CI, 0.04-0.50; P = 0.003). Moreover, multivariate Cox proportional HR analysis demonstrated EGFR clonal architecture as an independent prognostic indicator of the efficacy of EGFR-tyrosine kinase inhibitors (TKIs).CONCLUSIONS: Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer. EGFR mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs in NSCLC.

oncology
Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Xie Weimin,Liao Xiaoli,Yao Kaitao,Wang Hongxue,Fang Liang,Lin Yan,Chen Jun,Chen Falong,Li Yongqiang,LU Yongkui,Hu Xiaohua

2008-01-01

Abstract:Objective To investigated the association between the expression of DNA repair gene ERCC1 with the clinicopathology characteristics in patients with advanced noninitial chemotherapy treatment non-small cell lung cancer ( NSCLC ). Methods The ERCC1 expression in 64 NSCLC patients was examined with the method of immunohistochemistry, expression differences of ERCC1 and its relationship with the patients clinicopath- ology characteristics were analyzed. Results There were 28 cases expressing ERCC1 (43. 8%). Expression rates of ERCC1 in smokers was 27. 8% and was significantly lower than that in non-smokers (64.3%). The expression of ERCC1 in lung adenocarcinomas were lightly higher than squa- mous cell carcinomas,but the differenc was not significant. There were no significant differences between the expression of ERCC1 and the different TNM stages,gender,ages and pathological classification. Conclusion In non-small cell lung cancer,expression of ERCC1 was significantly higher in smokers than in non-smokers.
Dilemma and prospect of personalized therapy in non-small cell lung cancer

WANG Zhi-jie,WANG Jie

DOI: https://doi.org/10.3760/cma.j.issn.1006-9801.2010.01.006

2010-01-01

Abstract:Personalized therapy has became a main method to break through efficacy of chemotherapy in lung cancer. At present, we have got a few progressions in personalized therapy, but which are very limited. This review discourses upon the dilemma and hope of individualized treatment from the following ways:limitation of based on histology type to determine treatment regimens, undecided sequential therapy after failure of TKI as front-line therapy for advanced NSCLC patients with EGFR mutation, clinical study of maintenance therapy and EGFR mutation detection based on peripheral blood being trap or surrogate for tumor tissue to direct personalized TKI therapy.

Clinical Research of Individualized Therapy in Advanced Non-Small Cell Lung Cancer Guiding by & Nbsp;detection of ERCC1 Protein

Randomized and controlled clinical research of personalized therapy for advanced non-small cell lung cancer according to ERCC1 and RRM1

Clinical study on personalized treatment for advanced NSCLC guided by ERCC 1 protein detection

ERCC1 Protein As a Guide for Individualized Therapy of Late-Stage Advanced Non-Small Cell Lung Cancer.

Advances in Diagnosis and Treatment of HER2-positive Non-small Cell Lung Cancer

Clinical Research of Individualized Therapy in Advanced Esophageal Cancer Based on the ERCC1 C8092A Genotype.

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Expression of ERCC1,RRM1 and BRCA1 in Tissues of Advanced Non-Small Cell Lung Cancer

Expression of ERCC1 and BRCA1 Predict the Clinical Outcome of Non-Small Cell Lung Cancer in Patients Receiving Platinum-Based Chemotherapy.

Application of new ERCC1 antibody for molecular diagnosis of platinum chemotherapy in non-small cell lung cancer

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Analysis of A Case of Advanced Non-small Cell Lung Cancer Treated with Individualized Therapy

Can We Customize Chemotherapy? Individualizing Cytotoxic Regimens in Advanced Non–Small-Cell Lung Cancer

Long-term Survival with Targeted Therapy in an Advanced Non-Small Cell Lung Cancer Patient Based on Genetic Profiling.

New Approaches for Individual Treatment of Advanced Non-Small Cell Lung Cancer

Prognostic Significance of ERCC1 Mrna Expression in Patients with Non-Small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641)

Relation between the expression of ERCC1 and the clinicopathology characteristics in advanced non-small cell lung cancer

Dilemma and prospect of personalized therapy in non-small cell lung cancer